Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > NEWS - AlphaRx' Tuberculosis (TB) Drug Development Program Gaining Momentum

Abstract:
World renowned TB specialist intrigued by AlphaRx's nanoparticulate drug delivery platform joins forces with the Company and Russian scientists to develop effective TB treatments

NEWS - AlphaRx' Tuberculosis (TB) Drug Development Program Gaining Momentum

MARKHAM, Ontario, Canada | Posted on June 12th, 2007

AlphaRx Inc. (OTC Bulletin Board: ALRX) today announced that the U.S. Civilian Research and Development Foundation (CRDF) awarded a grant to scientists at the National Jewish Medical and Research Center, the Russian Research Center of Molecular Diagnostics and Therapy, and AlphaRx Inc. under the title "Development of the Drug Delivery Systems for Anti-Tuberculosis Drugs Based on Colloidal Lipid Nanoparticles". CRDF, based in Arlington, Virginia, is a nonprofit organization authorized by the U.S. Congress and established in 1995 by the National Science Foundation.

The Company believes that the development of colloidal formulations of anti-TB drugs based on nanoparticles is a promising and resource-consuming option for increasing efficacy, diminishing adverse side effects of these drugs, reducing dosing frequency, and potentially offering a solution to the substantial problem of treatment failure, due to patient non-compliance.

The Company is also pleased to announce the appointment of Dr. Leonid Heifets to its Scientist Advisory Board.

Dr. Heifets has been for many years involved in research related to mycobacteria. He is a professor in the Departments of Microbiology and Medicine (Pulmonology) of the School of Medicine at the University of Colorado Health Sciences Center in Denver, and Director of the Mycobacteriology Clinical Reference Laboratory at the National Jewish Medical and Research Center. Dr. Heifets is the Associate Editor of the International Journal of Tubercular Lung Disorders, and a member of several professional organizations whose work is related to mycobacterial diseases.

The Company recently published results of an animal study evaluated the efficacy of the Company's nanoparticle-encapsulated Streptomycin administered 2 times a week versus that of daily nonencapsulated drug against Mycobacterium tuberculosis infection in mice. Both treatments significantly reduced the bacterial count and mortality, suggesting that the Company's nanoparticle drug delivery system has potential in the treatment of tuberculosis. Further animal study is being conducted at the Beijing Tuberculosis and Thoracic Tumor Research Institute.

####

About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including arthritis, ocular infection & inflammation, tuberculosis and pneumonia.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

For more information, please click here

Contacts:
AGORACOM Investor Relations Corp.,

Copyright © AlphaRx Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

‘Oxford Instruments Young Nanoscientist India Award 2015’ to Prof. Arindam Ghosh April 20th, 2015

Iranian Female Professor Awarded UNESCO Medal in Nanoscience April 20th, 2015

Happily ever after: Scientists arrange protein-nanoparticle marriage: New biotech method could lead to development of HIV vaccine, targeted cancer treatment April 20th, 2015

Optical resonance-based biosensors designed for medical applications April 18th, 2015

Announcements

Happily ever after: Scientists arrange protein-nanoparticle marriage: New biotech method could lead to development of HIV vaccine, targeted cancer treatment April 20th, 2015

Nondestructive 3-D Imaging of Biological Cells with Sound April 20th, 2015

Advances in molecular electronics: Lights on -- molecule on: Researchers from Dresden and Konstanz succeed in light-controlled molecule switching April 20th, 2015

Yale-NUS, NUS and UT Austin researchers establish theoretical framework for graphene physics: Making strides towards using graphene to create new electronic devices April 20th, 2015

Human Interest/Art

To Conserve London's 300-Year-Old Masterpiece, Nanotech & Drones April 12th, 2015

2015 Nanonics Image Contest January 29th, 2015

OCSiAl supports NanoART Imagery Contest January 23rd, 2015

EnvisioNano: An image contest hosted by the National Nanotechnology Initiative (NNI) January 22nd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project